<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37190047</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Evaluation of 3D Human Intestinal Organoids as a Platform for EV-A71 Antiviral Drug Discovery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1138</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12081138</ELocationID><Abstract><AbstractText>Enteroviruses are a leading cause of upper respiratory tract, gastrointestinal, and neurological infections. Management of enterovirus-related diseases has been hindered by the lack of specific antiviral treatment. The pre-clinical and clinical development of such antivirals has been challenging, calling for novel model systems and strategies to identify suitable pre-clinical candidates. Organoids represent a new and outstanding opportunity to test antiviral agents in a more physiologically relevant system. However, dedicated studies addressing the validation and direct comparison of organoids versus commonly used cell lines are lacking. Here, we described the use of human small intestinal organoids (HIOs) as a model to study antiviral treatment against human enterovirus 71 (EV-A71) infection and compared this model to EV-A71-infected RD cells. We used reference antiviral compounds such as enviroxime, rupintrivir, and 2'-<i>C</i>-methylcytidine (2'CMC) to assess their effects on cell viability, virus-induced cytopathic effect, and viral RNA yield in EV-A71-infected HIOs and cell line. The results indicated a difference in the activity of the tested compounds between the two models, with HIOs being more sensitive to infection and drug treatment. In conclusion, the outcome reveals the value added by using the organoid model in virus and antiviral studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masmoudi</LastName><ForeName>Fatma</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Charles River Laboratories, 2333 CR Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OrganoVIR Labs, Department of Medical Microbiology, Amsterdam UMC Location Academic Medical Center, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos-Ferreira</LastName><ForeName>Nanci</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4995-5580</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, KU Leuven-Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajkrt</LastName><ForeName>Dasja</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5232-8206</Identifier><AffiliationInfo><Affiliation>OrganoVIR Labs, Pediatric Infectious Diseases, Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolthers</LastName><ForeName>Katja C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0003-1617-7049</Identifier><AffiliationInfo><Affiliation>OrganoVIR Labs, Department of Medical Microbiology, Amsterdam UMC Location Academic Medical Center, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeGroot</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8113-4200</Identifier><AffiliationInfo><Affiliation>Charles River Laboratories, 2333 CR Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlaming</LastName><ForeName>Maria L H</ForeName><Initials>MLH</Initials><AffiliationInfo><Affiliation>Charles River Laboratories, 2333 CR Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha-Pereira</LastName><ForeName>Joana</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8299-3787</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, KU Leuven-Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buti</LastName><ForeName>Ludovico</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Charles River Laboratories, 2333 CR Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">intestinal</Keyword><Keyword MajorTopicYN="N">organoids</Keyword></KeywordList><CoiStatement>F.M., L.B., M.L.H.V. and J.G. are employees of Charles River Laboratories, Leiden, the Netherlands. The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37190047</ArticleId><ArticleId IdType="pmc">PMC10136548</ArticleId><ArticleId IdType="doi">10.3390/cells12081138</ArticleId><ArticleId IdType="pii">cells12081138</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zell R., Delwart E., Gorbalenya A.E., Hovi T., King A.M.Q., Knowles N.J., Lindberg A.M., Pallansch M.A., Palmenberg A.C., Reuter G., et al. ICTV Virus Taxonomy Profile: Picornaviridae. J. Gen. Virol. 2017;98:2421–2422. doi: 10.1099/jgv.0.000911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000911</ArticleId><ArticleId IdType="pmc">PMC5725991</ArticleId><ArticleId IdType="pubmed">28884666</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.W., Cheng D., Wang J.R. Enterovirus A71: Virulence, Antigenicity, and Genetic Evolution over the Years. J. Biomed. Sci. 2019;26:1–9. doi: 10.1186/s12929-019-0574-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0574-1</ArticleId><ArticleId IdType="pmc">PMC6802317</ArticleId><ArticleId IdType="pubmed">31630680</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. J. Infect. Dis. 1974;129:304–309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region. J. Biomed. Sci. 2019;26:1–11. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Phyu W.K., Ong K.C., Wong K.T. Modelling Person-to-Person Transmission in an Enterovirus A71 Orally Infected Hamster Model of Hand-Foot-and-Mouth Disease and Encephalomyelitis. Emerg. Microbes Infect. 2017;6:1–9. doi: 10.1038/emi.2017.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2017.49</ArticleId><ArticleId IdType="pmc">PMC5567166</ArticleId><ArticleId IdType="pubmed">28698666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.-S., Yao Y.-C., Lin S.-C., Lee Y.-P., Wang Y.-F., Wang J.-R., Liu C.-C., Lei H.-Y., Yu C.-K. Retrograde Axonal Transport: A Major Transmission Route of Enterovirus 71 in Mice. J. Virol. 2007;81:8996–9003. doi: 10.1128/JVI.00236-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00236-07</ArticleId><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui Y.L.E., Timms P., Hafner L.M., Tan T.L., Tan K.H., Tan E.L. Characterisation of Enterovirus 71 Replication Kinetics in Human Colorectal Cell Line, HT29. Springerplus. 2013;2:1–8. doi: 10.1186/2193-1801-2-267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2193-1801-2-267</ArticleId><ArticleId IdType="pmc">PMC3696168</ArticleId><ArticleId IdType="pubmed">23875129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.L., Liu Y.G., Zhou Y.T., Zhao P., Ren H., Xiao M., Zhu Y.Z., Qi Z.T. Endophilin-A2-Mediated Endocytic Pathway Is Critical for Enterovirus 71 Entry into Caco-2 Cells. Emerg. Microbes Infect. 2019;8:773–786. doi: 10.1080/22221751.2019.1618686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2019.1618686</ArticleId><ArticleId IdType="pmc">PMC6542187</ArticleId><ArticleId IdType="pubmed">31132962</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., Koike S. Scavenger Receptor B2 Is a Cellular Receptor for Enterovirus 71. Nat. Med. 2009;15:798–802. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-Selectin Glycoprotein Ligand-1 Is a Functional Receptor for Enterovirus 71. Nat. Med. 2009;15:794–798. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Chuang H., Yang K.D. Sialylated Glycans as Receptor and Inhibitor of Enterovirus 71 Infection to DLD-1 Intestinal Cells. Virol. J. 2009;6:1–6. doi: 10.1186/1743-422X-6-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Ji L., Yuan X., Jin Y., Cardona C.J., Xing Z. Differential Regulation of TLR Signaling on the Induction of Antiviral Interferons in Human Intestinal Epithelial Cells Infected with Enterovirus 71. PLoS ONE. 2016;11:e0152177. doi: 10.1371/journal.pone.0152177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152177</ArticleId><ArticleId IdType="pmc">PMC4805281</ArticleId><ArticleId IdType="pubmed">27007979</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreni G., Aknouch I., Ras M., Brouwer L., Spijker R., Calitz C., Stittelaar K.J., Sridhar A., Wolthers K.C., Pajkrt D. Bridging the Gap between Emerging Models and Humans by Learning from Polio Animal Studies: A Systematic Review. Clin. Transl. Discov. 2022;2:e42. doi: 10.1002/ctd2.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctd2.42</ArticleId></ArticleIdList></Reference><Reference><Citation>Spence J.R., Mayhew C.N., Rankin S.A., Kuhar M.F., Vallance J.E., Tolle K., Hoskins E.E., Kalinichenko V.V., Wells S.I., Zorn A.M., et al. Directed Differentiation of Human Pluripotent Stem Cells into Intestinal Tissue in Vitro. Nature. 2011;470:105–109. doi: 10.1038/nature09691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09691</ArticleId><ArticleId IdType="pmc">PMC3033971</ArticleId><ArticleId IdType="pubmed">21151107</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker N., van Es J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., Haegebarth A., Korving J., Begthel H., Peters P.J., et al. Identification of Stem Cells in Small Intestine and Colon by Marker Gene Lgr5. Nature. 2007;449:1003–1007. doi: 10.1038/nature06196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06196</ArticleId><ArticleId IdType="pubmed">17934449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., et al. Single Lgr5 Stem Cells Build Crypt-Villus Structures in Vitro without a Mesenchymal Niche. Nature. 2009;459:262–265. doi: 10.1038/nature07935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07935</ArticleId><ArticleId IdType="pubmed">19329995</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Duan X., Yang L., Nilsson-Payant B.E., Wang P., Duan F., Tang X., Yaron T.M., Zhang T., Uhl S., et al. Identification of SARS-CoV-2 Inhibitors Using Lung and Colonic Organoids. Nature. 2021;589:270–275. doi: 10.1038/s41586-020-2901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2901-9</ArticleId><ArticleId IdType="pmc">PMC8034380</ArticleId><ArticleId IdType="pubmed">33116299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Tan M., Zhong W., Xia M., Huang P., Jiang X. Human Intestinal Organoids Express Histo-Blood Group Antigens, Bind Norovirus VLPs, and Support Limited Norovirus Replication. Sci. Rep. 2017;7:12621. doi: 10.1038/s41598-017-12736-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-12736-2</ArticleId><ArticleId IdType="pmc">PMC5626734</ArticleId><ArticleId IdType="pubmed">28974702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S., Hisaie K., Kurokawa S., Suzuki A., Sakon N., Uchida Y., Yuki Y., Kiyono H. Human Norovirus Propagation in Human Induced Pluripotent Stem Cell–Derived Intestinal Epithelial Cells. Cell. Mol. Gastroenterol. Hepatol. 2019;7:686. doi: 10.1016/j.jcmgh.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6477164</ArticleId><ArticleId IdType="pubmed">30543870</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond C.G., Bolock A.M., Ma C., Luke C.J., Good M., Coyne C.B. Enteroviruses Infect Human Enteroids and Induce Antiviral Signaling in a Cell Lineage-Specific Manner. Proc. Natl. Acad. Sci. USA. 2017;114:1672–1677. doi: 10.1073/pnas.1617363114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1617363114</ArticleId><ArticleId IdType="pmc">PMC5320971</ArticleId><ArticleId IdType="pubmed">28137842</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang J.O., Zhou J., Zhao X., Li C., Zou Z., Yin F., Yuan S. Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses. Biomedicines. 2021;9:88. doi: 10.3390/biomedicines9010088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9010088</ArticleId><ArticleId IdType="pmc">PMC7831294</ArticleId><ArticleId IdType="pubmed">33477611</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkbeiner S.R., Zeng X.-L., Utama B., Atmar R.L., Shroyer N.F., Estes M.K. Stem Cell-Derived Human Intestinal Organoids as an Infection Model for Rotaviruses. mBio. 2012;3:1–6. doi: 10.1128/mBio.00159-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00159-12</ArticleId><ArticleId IdType="pmc">PMC3398537</ArticleId><ArticleId IdType="pubmed">22761392</ArticleId></ArticleIdList></Reference><Reference><Citation>Good C., Wells A.I., Coyne C.B. Type III Interferon Signaling Restricts Enterovirus 71 Infection of Goblet Cells. Sci. Adv. 2019;5:1–12. doi: 10.1126/sciadv.aau4255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aau4255</ArticleId><ArticleId IdType="pmc">PMC6402847</ArticleId><ArticleId IdType="pubmed">30854425</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz B.A., Vance L.M. Sequence Determinants of 3A-Mediated Resistance to Enviroxime in Rhinoviruses and Enteroviruses. J. Virol. 1996;70:4854–4857. doi: 10.1128/jvi.70.7.4854-4857.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.7.4854-4857.1996</ArticleId><ArticleId IdType="pmc">PMC190432</ArticleId><ArticleId IdType="pubmed">8676522</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Webber S.E., Marakovits J.T., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Ford C.E., et al. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as L-Glutamine Replacements. J. Med. Chem. 1999;42:1213–1224. doi: 10.1021/jm9805384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9805384</ArticleId><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierra C., Amador A., Benzaria S., Cretton-Scott E., D’Amours M., Mao J., Mathieu S., Moussa A., Bridges E.G., Standring D.N., et al. Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2′-C-Methylcytidine. J. Med. Chem. 2006;49:6614–6620. doi: 10.1021/jm0603623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0603623</ArticleId><ArticleId IdType="pubmed">17064080</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena K., Blutt S.E., Ettayebi K., Zeng X.-L., Broughman J.R., Crawford S.E., Karandikar U.C., Sastri N.P., Conner M.E., Opekun A.R., et al. Human Intestinal Enteroids: A New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology. J. Virol. 2016;90:43–56. doi: 10.1128/JVI.01930-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01930-15</ArticleId><ArticleId IdType="pmc">PMC4702582</ArticleId><ArticleId IdType="pubmed">26446608</ArticleId></ArticleIdList></Reference><Reference><Citation>Holly M.K., Smith J.G. Adenovirus Infection of Human Enteroids Reveals Interferon Sensitivity and Preferential Infection of Goblet Cells. J. Virol. 2018;92:1–15. doi: 10.1128/JVI.00250-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00250-18</ArticleId><ArticleId IdType="pmc">PMC5899204</ArticleId><ArticleId IdType="pubmed">29467318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Li C., Zhao G., Chu H., Wang D., Yan H.H.-N., Poon V.K.-M., Wen L., Wong B.H.-Y., Zhao X., et al. Human Intestinal Tract Serves as an Alternative Infection Route for Middle East Respiratory Syndrome Coronavirus. Sci. Adv. 2017;3:eaao4966. doi: 10.1126/sciadv.aao4966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aao4966</ArticleId><ArticleId IdType="pmc">PMC5687858</ArticleId><ArticleId IdType="pubmed">29152574</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Lee H., Thibaut H.J., Lanko K., Rivero-Buceta E., Bator C., Martinez-Gualda B., Dallmeier K., Delang L., Leyssen P., et al. Viral Engagement with Host Receptors Blocked by a Novel Class of Tryptophan Dendrimers That Targets the 5-Fold-Axis of the Enterovirus—A 71 Capsid. PLoS Pathog. 2019;15:e1007760. doi: 10.1371/journal.ppat.1007760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007760</ArticleId><ArticleId IdType="pmc">PMC6590834</ArticleId><ArticleId IdType="pubmed">31071193</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Cellular Kinase Inhibitors That Suppress Enterovirus Replication Have a Conserved Target in Viral Protein 3A Similar to That of Enviroxime. J. Gen. Virol. 2009;90:1869–1879. doi: 10.1099/vir.0.012096-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.012096-0</ArticleId><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Takebe Y., Wakita T., Shimizu H. A Bifunctional Anti-Enterovirus Compound That Inhibits Replication and the Early Stage of Enterovirus 71 Infection. J. Gen. Virol. 2010;91:2734–2744. doi: 10.1099/vir.0.023374-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.023374-0</ArticleId><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Characterization of Pharmacologically Active Compounds That Inhibit Poliovirus and Enterovirus 71 Infectivity. J. Gen. Virol. 2008;89:2518–2530. doi: 10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M., Thibaut H.J., Van Der Linden L., Lanke K., Heggermont W., Ireland S., Andrews R., Arimilli M., Al-Tel T.H., De Clercq E., et al. Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009;53:1850–1857. doi: 10.1128/AAC.00934-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00934-08</ArticleId><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J., Delong D.C., Wallace J., Jones R.W., Reed S.E., Tyrrell D.A.J. The Activity of Enviroxime Against Rhinovirus Infection in Man. Lancet. 1981;317:1342–1344. doi: 10.1016/S0140-6736(81)92520-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(81)92520-4</ArticleId><ArticleId IdType="pubmed">6113314</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller F.D., Monto A.S., DeLong D.C., Exelby A., Bryan E.R., Srivastava S. Controlled Trial of Enviroxime against Natural Rhinovirus Infections in a Community. Antimicrob. Agents Chemother. 1985;27:102–106. doi: 10.1128/AAC.27.1.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.27.1.102</ArticleId><ArticleId IdType="pmc">PMC176213</ArticleId><ArticleId IdType="pubmed">2984980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith G.J., Zalman L.S. Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrob. Agents Chemother. 2003;47:3907–3916. doi: 10.1128/AAC.47.12.3907-3916.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3907-3916.2003</ArticleId><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee D.F., Evans W.J., Nicolaou K.C., Tarbet E.B., Day C.W. Susceptibilities of Enterovirus D68, Enterovirus 71, and Rhinovirus 87 Strains to Various Antiviral Compounds. Antivir. Res. 2016;131:61–65. doi: 10.1016/j.antiviral.2016.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="pubmed">27063860</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroulios G., Brown T., Moreni G., Kondro D., Dei A., Eaves A., Louis S., Hou J., Chang W., Pajkrt D., et al. Apical-out Airway Organoids as a Platform for Studying Viral Infections and Screening for Antiviral Drugs. Sci. Rep. 2022;12:7673. doi: 10.1038/s41598-022-11700-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11700-z</ArticleId><ArticleId IdType="pmc">PMC9089294</ArticleId><ArticleId IdType="pubmed">35538146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Lovell S., Tiew K.-C., Mandadapu S.R., Alliston K.R., Battaile K.P., Groutas W.C., Chang K.-O. Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses. J. Virol. 2012;86:11754–11762. doi: 10.1128/JVI.01348-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01348-12</ArticleId><ArticleId IdType="pmc">PMC3486288</ArticleId><ArticleId IdType="pubmed">22915796</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Song Z., Qin B., Zhang X., Chen L., Hu Y., Yuan Z. Rupintrivir Is a Promising Candidate for Treating Severe Cases of Enterovirus-71 Infection: Evaluation of Antiviral Efficacy in a Murine Infection Model. Antivir. Res. 2013;97:264–269. doi: 10.1016/j.antiviral.2012.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Boda B., Benaoudia S., Huang S., Bonfante R., Wiszniewski L., Tseligka E.D., Tapparel C., Constant S. Antiviral Drug Screening by Assessing Epithelial Functions and Innate Immune Responses in Human 3D Airway Epithelium Model. Antivir. Res. 2018;156:72–79. doi: 10.1016/j.antiviral.2018.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.06.007</ArticleId><ArticleId IdType="pmc">PMC7113743</ArticleId><ArticleId IdType="pubmed">29890184</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetto M., Van Dycke J., Neyts J., Brancale A., Rocha-Pereira J. Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy. Viruses. 2019;11:173. doi: 10.3390/v11020173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11020173</ArticleId><ArticleId IdType="pmc">PMC6409847</ArticleId><ArticleId IdType="pubmed">30791582</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J.Y. Addressing the Selectivity and Toxicity of Antiviral Nucleosides. Antivir. Chem. Chemother. 2018;26:1–8. doi: 10.1177/2040206618758524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206618758524</ArticleId><ArticleId IdType="pmc">PMC5890540</ArticleId><ArticleId IdType="pubmed">29534607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrazin C., Zeuzem S. Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection. Gastroenterology. 2010;138:447–462. doi: 10.1053/j.gastro.2009.11.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.11.055</ArticleId><ArticleId IdType="pubmed">20006612</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown N.A. Progress towards Improving Antiviral Therapy for Hepatitis C with Hepatitis C Virus Polymerase Inhibitors. Part I: Nucleoside Analogues. Expert Opin. Investig. Drugs. 2009;18:709–725. doi: 10.1517/13543780902854194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543780902854194</ArticleId><ArticleId IdType="pubmed">19426125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson L., Kirk R. High Drug Attrition Rates—Where Are We Going Wrong? Nat. Rev. Clin. Oncol. 2011;8:189–190. doi: 10.1038/nrclinonc.2011.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2011.34</ArticleId><ArticleId IdType="pubmed">21448176</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Rodríguez I., van Eijk H., Koen G., Pajkrt D., Sridhar A., Wolthers K.C. Parechovirus A Infection of the Intestinal Epithelium: Differences Between Genotypes A1 and A3. Front. Cell. Infect. Microbiol. 2021;11:1–11. doi: 10.3389/fcimb.2021.740662.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.740662</ArticleId><ArticleId IdType="pmc">PMC8591172</ArticleId><ArticleId IdType="pubmed">34790587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.X., Chu J.J.H. Antiviral Screen Identifies EV71 Inhibitors and Reveals Camptothecin-Target, DNA Topoisomerase 1 as a Novel EV71 Host Factor. Antivir. Res. 2017;143:122–133. doi: 10.1016/j.antiviral.2017.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.04.008</ArticleId><ArticleId IdType="pubmed">28427827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>